| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GRIN2B |
| Uniprot No | Q13224 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 127-236aa |
| 氨基酸序列 | HGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYF PGYQDFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSP IILLYCTKEE |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与GRIN2B重组蛋白相关的代表性文献摘要(文献标题与内容为虚构示例，仅供格式参考)：
1. **文献名称**: "Expression and Purification of Functional GRIN2B Recombinant Protein in HEK293 Cells"
**作者**: Smith A, et al.
**摘要**: 本研究建立了人源GRIN2B蛋白在HEK293细胞中的重组表达系统，通过优化跨膜结构域和亲和层析技术获得高纯度蛋白，并验证其在体外电生理实验中的功能活性。
2. **文献名称**: "Structural Insights into GRIN2B NMDA Receptor Subunit via Cryo-EM Analysis"
**作者**: Chen L, et al.
**摘要**: 利用冷冻电镜解析GRIN2B重组蛋白与谷氨酸结合的结构特征，揭示了其离子通道门控机制，为神经退行性疾病相关突变位点的功能研究提供结构基础。
3. **文献名称**: "GRIN2B Recombinant Protein Modulates Synaptic Plasticity in Murine Neuronal Models"
**作者**: Kim J, et al.
**摘要**: 通过体外重组GRIN2B蛋白递送至小鼠神经元，证明其可逆转由GRIN2B缺失引起的突触可塑性异常，为自闭症谱系障碍的靶向治疗提供实验依据。
(注：以上文献为示例性质，实际研究需通过PubMed或Google Scholar检索真实文献。)
**Background of GRIN2B Recombinant Protein**
GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) encodes the GluN2B subunit of N-methyl-D-aspartate (NMDA) receptors, a subclass of ionotropic glutamate receptors critical for synaptic plasticity, learning, and memory. These receptors are heterotetramers, typically composed of two GluN1 subunits and two GluN2 subunits (e.g., GluN2B). GRIN2B-derived GluN2B is predominantly expressed in the central nervous system, particularly during early development, and regulates calcium permeability, receptor trafficking, and synaptic signaling.
Recombinant GRIN2B protein is engineered to study the structure, function, and interactions of GluN2B in vitro. It is commonly produced using heterologous expression systems, such as mammalian (HEK293) or insect (Sf9) cells, to ensure proper post-translational modifications. The recombinant protein often includes tags (e.g., His-tag, FLAG) for purification and detection. Researchers use it to investigate NMDA receptor assembly, ligand binding (e.g., glutamate, glycine), and the impact of mutations linked to neurological disorders.
Dysregulation of GRIN2B is associated with neurodevelopmental conditions, including autism spectrum disorder, epilepsy, and intellectual disability. Pathogenic variants in GRIN2B alter receptor kinetics, leading to excitatory-inhibitory imbalance. Recombinant GRIN2B enables mechanistic studies of these mutations and screens for therapeutic compounds targeting GluN2B-containing NMDA receptors. Additionally, it aids in structural biology (e.g., cryo-EM studies) to visualize receptor conformations and drug-binding sites.
Overall, GRIN2B recombinant protein serves as a vital tool for dissecting NMDA receptor biology and developing treatments for neurological diseases.
×
